BR0313729A - Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo - Google Patents

Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo

Info

Publication number
BR0313729A
BR0313729A BR0313729-5A BR0313729A BR0313729A BR 0313729 A BR0313729 A BR 0313729A BR 0313729 A BR0313729 A BR 0313729A BR 0313729 A BR0313729 A BR 0313729A
Authority
BR
Brazil
Prior art keywords
estrogen
bmp
methods
responsive element
estrogen responsive
Prior art date
Application number
BR0313729-5A
Other languages
English (en)
Inventor
Peter Van Nest Bodine
Dan Gazit
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0313729A publication Critical patent/BR0313729A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

"ELEMENTO RESPONDENTE A ESTROGêNIO BMP-2 E MéTODOS DE USO DO MESMO". A presente invenção refere-se a um ácido nucléico isolado correspondendo à região reguladora BMP-2, ou um fragmento da mesma, compreendendo um elemento respondente a estrogênio, vetor compreendendo o mesmo e células que compreendem, o dito vetor. Em outra concretização, a invenção proporciona métodos para identificar um agonista de estrogênio, antagonista de estrogênio e um agente terapêutico. Em outra concretização, a invenção proporciona métodos para tratar condições que são associadas com insuficiência de estrogênio ou com falta de resposta a estrogênio externo ou de agonistas do mesmo.
BR0313729-5A 2002-08-16 2003-08-18 Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo BR0313729A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40402402P 2002-08-16 2002-08-16
PCT/US2003/023271 WO2004016639A1 (en) 2002-08-16 2003-08-18 Bmp-2 estrogen responsive element and methods of using the same

Publications (1)

Publication Number Publication Date
BR0313729A true BR0313729A (pt) 2005-06-21

Family

ID=31888312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313729-5A BR0313729A (pt) 2002-08-16 2003-08-18 Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo

Country Status (14)

Country Link
US (1) US20050271637A1 (pt)
EP (1) EP1534731A4 (pt)
JP (1) JP2006500925A (pt)
KR (1) KR20050083635A (pt)
CN (1) CN1753904A (pt)
AU (1) AU2003261246A1 (pt)
BR (1) BR0313729A (pt)
CA (1) CA2497304A1 (pt)
CO (1) CO5721011A2 (pt)
MX (1) MXPA05001694A (pt)
NO (1) NO20050935L (pt)
RU (1) RU2005107330A (pt)
WO (1) WO2004016639A1 (pt)
ZA (1) ZA200502131B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (es) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2484372A1 (en) 2007-02-09 2012-08-08 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20230761T1 (hr) 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke
CN107970445B (zh) * 2009-03-30 2021-09-07 阿塞勒隆制药公司 Bmp-alk3拮抗剂和促进骨生长的用途
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA BINDING AGENTS AND USES THEREOF
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
CA2951926C (en) 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
JPS59500735A (ja) * 1983-04-18 1984-04-26 エス・ア−ル・アイ・インタ−ナシヨナル 人間の癌診断のための方法および試験キツト
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
EP0944312B9 (en) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions and methods for stimulating bone growth
JPH11313673A (ja) * 1998-04-30 1999-11-16 Hoechst Marion Roussel Kk ヒトｂｍｐ−２プロモーターおよびこれを用いた骨関連物質の探索法
US6630304B1 (en) * 2000-09-14 2003-10-07 Decode Genetics Ehf. Human osteoporosis gene

Also Published As

Publication number Publication date
MXPA05001694A (es) 2005-07-22
US20050271637A1 (en) 2005-12-08
RU2005107330A (ru) 2005-10-10
KR20050083635A (ko) 2005-08-26
AU2003261246A1 (en) 2004-03-03
CA2497304A1 (en) 2004-02-26
NO20050935L (no) 2005-05-10
CN1753904A (zh) 2006-03-29
EP1534731A1 (en) 2005-06-01
JP2006500925A (ja) 2006-01-12
ZA200502131B (en) 2005-09-21
EP1534731A4 (en) 2006-05-17
WO2004016639A1 (en) 2004-02-26
CO5721011A2 (es) 2007-01-31

Similar Documents

Publication Publication Date Title
BR0313729A (pt) Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo
BR0114754A (pt) Compostos não-imidazóis
BR9707136A (pt) Derivados morfinóides condesados em heterociclo (ii)
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
BR0209919A (pt) Composições pesticidas lìquidas estáveis
BR0207977A (pt) Métodos de combinação de inibição de crescimento tumoral com um antagonista de receptor de fator de crescimento endotelial
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
BR9806752A (pt) Ftalazinonas.
BRPI0400860A (pt) Sistema e método para facilitar perfilamento de aplicações
NO20085251L (no) Steroide sapogeninger samt deres derivater for behandling av Alzheimers sykdom
BRPI0409701A (pt) ligantes de receptores de canabinóides e seus usos
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
WO2003000853A3 (en) Protein aggregation assays and uses thereof
WO2004021174A3 (en) Scheduler for use in a microprocessor that supports data-speculative-execution
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
BRPI0410177A (pt) métodos de distribuir um ingrediente
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
HRP20080413T3 (en) Medicament for the treatment of fungal infections, particularly aspergillosis
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
BRPI0411095A (pt) derivados de imidazol
DE60101486D1 (de) Verwendung von Polyaminosäurederivate als Konservierungsmittel

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired